CDK6 inhibits de novo lipogenesis in white adipose tissues but not in the liver

Alexander J. Hu,Wei Li,Calvin Dinh,Yongzhao Zhang,Jamie K. Hu,Stefano G. Daniele,Xiaoli Hou,Zixuan Yang,John M. Asara,Guo-fu Hu,Stephen R. Farmer,Miaofen G. Hu
DOI: https://doi.org/10.1038/s41467-024-45294-z
IF: 16.6
2024-02-05
Nature Communications
Abstract:Abstract Increased de novo lipogenesis (DNL) in white adipose tissue is associated with insulin sensitivity. Under both Normal-Chow-Diet and High-Fat-Diet, mice expressing a kinase inactive Cyclin-dependent kinase 6 ( Cdk6 ) allele ( K43M ) display an increase in DNL in visceral white adipose tissues (VAT) as compared to wild type mice ( WT ), accompanied by markedly increased lipogenic transcriptional factor Carbohydrate-responsive element-binding proteins (CHREBP) and lipogenic enzymes in VAT but not in the liver. Treatment of WT mice under HFD with a CDK6 inhibitor recapitulates the phenotypes observed in K43M mice. Mechanistically, CDK6 phosphorylates AMP-activated protein kinase, leading to phosphorylation and inactivation of acetyl-CoA carboxylase, a key enzyme in DNL. CDK6 also phosphorylates CHREBP thus preventing its entry into the nucleus. Ablation of runt related transcription factor 1 in K43M mature adipocytes reverses most of the phenotypes observed in K43M mice. These results demonstrate a role of CDK6 in DNL and a strategy to alleviate metabolic syndromes.
multidisciplinary sciences
What problem does this paper attempt to address?
The paper aims to address the following issues: 1. **Investigate the role of CDK6 in white adipose tissue (WAT)**: The paper explores the impact of CDK6 on de novo lipogenesis (DNL) in WAT. The study found that the loss of CDK6 kinase activity leads to an increase in DNL in WAT, an effect not observed in the liver. 2. **Therapeutic strategies for metabolic syndrome**: Obesity and its related metabolic diseases remain significant medical challenges. Enhancing DNL in WAT by inhibiting CDK6 could become a new therapeutic strategy, potentially improving insulin sensitivity and other metabolic abnormalities. 3. **Study of molecular mechanisms**: The paper provides a detailed analysis of how CDK6 regulates the DNL process through the phosphorylation of key proteins such as AMPK and CHREBP. Additionally, gene knockout experiments further validated the importance of RUNX1 as a downstream effector of CDK6. In summary, the paper primarily investigates the function of CDK6 in WAT and its regulatory mechanism on DNL, proposing a potential strategy for treating obesity and related metabolic diseases.